Video

Dr. Villanueva on Eliminating Tumor Heterogeneity in Patients With HCC

Augusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai, discusses mutations and gene signatures for patients with hepatocellular carcinoma, a topic he presented at the 2020 Gastrointestinal Cancers Symposium.

Augusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai Hospital, discusses mutations and gene signatures for patients with hepatocellular carcinoma (HCC)—a topic he presented at the 2020 Gastrointestinal Cancers Symposium.

The goal of the study is to better understand the characteristics of heterogeneous tumors, in order to option better genetic information when performing biopsies. The investigators found that in 30% of patients, there is significant heterogeneity at the level of gene expression, which has a significant connection to the composition of the tumor microenvironment, says Villaneuva.

There may be a solution to heterogeneous tumors, and Villaneuva explains that liquid biopsies may play a role in deriving novel biomarkers for HCC. It has been shown that analyzing plasma can make it easier to detect driver genes in patients with HCC. Similarly, it is known that circulating tumor cells and exosomes can be isolated. These both contain DNA, RNA, and microRNA that can be analyzed to provide biomarkers for HCC.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity